â– LECTURE OVERVIEW: Systemic Lupus Erythematosus (SLE) is a multi-system, autoimmune disease characterized by a profound loss of self-tolerance and the production of diverse autoantibodies.
â– IMMUNOPATHOGENIC DETAILS:
1. Clearance Defects: Defective clearance of apoptotic debris exposes self-nuclear antigens to the immune system, initiating autoantibody production.
2. Core Autoantibody Profiling:
- Antinuclear Antibodies (ANA): Target nuclear antigens. Present in >95% of patients with active SLE. (High sensitivity, low specificity; standard screening test).
- Anti-dsDNA: Highly specific for SLE (>97%). Titers correlate with disease activity and the development of severe lupus nephritis.
- Anti-Smith (Sm): Highly specific for SLE (>99%). Targets small nuclear ribonucleoproteins (snRNPs); titers do not correlate with disease activity.
- Anti-Ro (SSA) and Anti-La (SSB): Associated with neonatal lupus and congenital heart block.
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– SURGICAL COMPASS & ANATOMICAL CORRELATION:
Dissection lines must respect established fascial boundaries to prevent neurovascular traction injuries and secure excellent diagnostic margins.
[HY-BOARD-1192]
🌟 Dynamic Clinical Key:
Antiphospholipid Antibodies (e.g., anti-beta-2-glycoprotein 1, anticardiolipin) are also common in SLE. Paradoxically, they prolong the in vitro partial thromboplastin time (aPTT) by interfering with phospholipids, but in vivo they cause a hypercoagulable state with recurrent arterial and venous thromboses. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Verify landmarks dynamically with gentle palpation and specialized intraoperative markers.